RELEASE: Significant efficiencies in case intake in newly launched generative AI solution

(Information sent by the signatory company).

RELEASE: Significant efficiencies in case intake in newly launched generative AI solution

(Information sent by the signatory company)

- Significant case intake efficiencies found in newly launched generative AI solution for life sciences

Advanced Intake™ demonstrates gains of up to 65% efficiency in adverse case intake and 90% accuracy and quality in data extraction.

BOSTON, April 23, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today revealed details about its Advanced Intake solution powered by LifeSphere NavaX, the advanced cognitive computing engine from next generation of the company. Advanced Intake automates security data collection and subsequent workflows.

Faced with increasing volumes of data from multiple and diverse sources, Advanced Intake leverages the latest intelligent automation technologies, including generative AI and large language models (LLM), to revolutionize adverse event (AE) intake.

As demonstrated in early pilot testing, Advanced Intake delivers efficiency gains of up to 65% and demonstrates 90% data extraction accuracy and quality.

Advanced Intake features dynamic data extraction, meaning the system can intelligently process forms regardless of number, variation, or formatting inconsistencies. With dynamic data extraction, no form configuration is required. The traditional manual case processing process previously required to account for variability is revolutionized with Advanced Intake, increasing efficiency in the overall handling of EA case data.

Organizations that take advantage of Advanced Intake gain additional benefits such as:

Commenting on the importance of Advanced Intake to the industry, Ann-Marie Orange, Chief Information Officer and Global Head of R&D at ArisGlobal, said: "The life sciences industry is crying out for practical applications and technological expertise around to GenAI, and ArisGlobal is prepared to meet these needs. Advanced Intake is an example of the innovation we are providing to meet this demand: organizations can overcome growing case volumes and face the challenges of struggling to find fluid, easy-to-use technologies. implement that provide proven value.

"Specifically, pharmaceutical companies have been asking for more modern and efficient ways to execute case intake and safety data collection. Our team at ArisGlobal is excited to not only bring advanced intake to market, but also the fact that we can bring it into the sandbox for our customers. We have long partnered with our customers to pioneer intelligent pharmacovigilance, and the launch of this product is another milestone in creating a comprehensive toolset of intelligent, integrated capabilities. as part of the LifeSphere ecosystem."

ArisGlobal, which announced a series of product innovations at its recent Breakthrough2024 conference in London, UK, is the first life sciences R&D technology company to introduce targeted solutions that make impactful use of generative AI in the industry. . Meanwhile, the company continues to host the industry-leading GenAI Council, which brings together top pharmaceutical executives, academics and AI thought leaders to further drive the adoption of next-generation technologies in life sciences.

About ArisGlobalArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn or visit

Logo -

View original content: